BIOLOGIC AND TARGETED SYSTEMIC THERAPIES FOR MODERATE-TO-SEVERE PLAQUE PSORIASIS IN EUROPE: A REVIEW OF MECHANISMS, EFFICACY, SAFETY, AND CLINICAL POSITIONING
DOI:
https://doi.org/10.31435/ijitss.2(50).2026.5305Keywords:
Psoriasis, Plaque Psoriasis, Biologic Therapy, Targeted Therapy, TNF-Α Inhibitors, IL-17 Inhibitors, IL-23 InhibitorsAbstract
Major advances in the understanding of psoriasis immunopathogenesis have reshaped the treatment of moderate-to-severe plaque psoriasis. Identification of tumor necrosis factor-α (TNF-α) and the IL-23/Th17 axis as central drivers of disease has led to the development of biologic and targeted systemic therapies capable of achieving substantially improved disease control and patient outcomes.
This review examines the principal biologic and targeted systemic therapies currently used in Europe, including TNF-α, IL-12/23, IL-17, and IL-23 inhibitors, as well as apremilast. We discuss their mechanisms of action, clinical efficacy, durability of response, safety profiles, and therapeutic positioning on the basis of pivotal trials, extension studies, network meta-analyses, and real-world evidence.
Among currently available agents, IL-17 and IL-23 inhibitors generally provide the greatest levels of skin clearance, whereas TNF-α inhibitors continue to occupy an important place in selected clinical contexts, particularly in patients with concomitant psoriatic arthritis. Ustekinumab remains a well-established option with durable efficacy and convenient administration, while apremilast retains relevance in patients for whom an oral non-biologic approach is preferred.
Taken together, current evidence supports a shift from broad immunosuppression toward mechanism-based, individualized therapy. In contemporary psoriasis care, treatment selection should be guided not only by efficacy, but also by long-term safety, durability, comorbidities, and patient-specific considerations.
References
Abrouk, M., Nakamura, M., Zhu, T. H., Farahnik, B., Koo, J., & Bhutani, T. (2017). The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients. The Journal of Dermatological Treatment, 28(6), 488–491. https://doi.org/10.1080/09546634.2016.1278198
Aggarwal, P., & Fleischer, A. B. (2024). IL-17 and IL-23 inhibitors have the fastest time to meaningful clinical response for plaque psoriasis: A network meta-analysis. Journal of Clinical Medicine, 13(17). https://doi.org/10.3390/jcm13175139
Armstrong, A., Papp, K. A., Lebwohl, M., Savage, L. J., Yamanaka, K., Vlase, D. E., Warham, R., Lambert, J., López Pinto, J. M., Wixted, K., & Thaçi, D. (2026). Bimekizumab impact on patient-reported outcomes in plaque psoriasis: 4-year results from BE SURE, BE VIVID, BE READY, and BE BRIGHT. Dermatology and Therapy, 16(1). https://doi.org/10.1007/s13555-025-01595-9
Armstrong, A. W., & Read, C. (2020). Pathophysiology, clinical presentation, and treatment of psoriasis: A review. JAMA, 323(19), 1945–1960. https://doi.org/10.1001/jama.2020.4006
Augustin, M., Abeysinghe, S., Mallya, U., Qureshi, A., Roskell, N., McBride, D., Papavassillis, C., & Gelfand, J. (2015). Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response: Results of a phase 2 regimen-finding trial. Journal of the European Academy of Dermatology and Venereology, 30(4), 645. https://doi.org/10.1111/jdv.13478
Augustin, M., Lambert, J., Zema, C., Thompson, E. H. Z., Yang, M., Wu, E. Q., Garcia-Horton, V., Geng, Z., Valdes, J. M., Joshi, A., & Gordon, K. B. (2020). Effect of risankizumab on patient-reported outcomes in moderate to severe psoriasis: The UltIMMa-1 and UltIMMa-2 randomized clinical trials. JAMA Dermatology, 156(12), 1344–1353. https://doi.org/10.1001/jamadermatol.2020.3617
European Medicines Agency. (n.d.). Bimzelx. Retrieved March 13, 2026, from https://www.ema.europa.eu/en/medicines/human/EPAR/bimzelx
Blauvelt, A., & Chiricozzi, A. (2018). The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clinical Reviews in Allergy & Immunology, 55(3), 379. https://doi.org/10.1007/s12016-018-8702-3
Blauvelt, A., Langley, R. G., Lebwohl, M., Strober, B., Warren, R. B., Puig, L., Morita, A., Gordon, K. B., Fernandez-Peñas, P., Kavanagh, S., López Pinto, J. M., Lambert, J., Hoepken, B., Deherder, D., Cross, N., & Thaçi, D. (2025). Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial. Journal of the American Academy of Dermatology, 93(3), 644–653. https://doi.org/10.1016/j.jaad.2025.04.038
Blauvelt, A., Papp, K. A., Griffiths, C. E. M., Randazzo, B., Wasfi, Y., Shen, Y. K., Li, S., & Kimball, A. B. (2017). Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator trial. Journal of the American Academy of Dermatology, 76(3), 405–417. https://doi.org/10.1016/j.jaad.2016.11.041
Blauvelt, A., Paul, C., van de Kerkhof, P., Warren, R. B., Gottlieb, A. B., Langley, R. G., Brock, F., Arendt, C., Boehnlein, M., Lebwohl, M., & Reich, K. (2021). Long-term safety of certolizumab pegol in plaque psoriasis: Pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies. The British Journal of Dermatology, 184(4), 640–651. https://doi.org/10.1111/bjd.19314
Blauvelt, A., Sofen, H., Papp, K., Gooderham, M., Tyring, S., Zhao, Y., Lowry, S., Mendelsohn, A., Parno, J., & Reich, K. (2019a). Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: A pooled analysis of two randomized controlled trials. Journal of the European Academy of Dermatology and Venereology, 33(12), 2305. https://doi.org/10.1111/jdv.15862
Blauvelt, A., Sofen, H., Papp, K., Gooderham, M., Tyring, S., Zhao, Y., Lowry, S., Mendelsohn, A., Parno, J., & Reich, K. (2019b). Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: A pooled analysis of two randomized controlled trials. Journal of the European Academy of Dermatology and Venereology, 33(12), 2305–2312. https://doi.org/10.1111/jdv.15862
Crowley, J. J., Warren, R. B., & Cather, J. C. (2019). Safety of selective IL-23p19 inhibitors for the treatment of psoriasis. Journal of the European Academy of Dermatology and Venereology, 33(9), 1676–1684. https://doi.org/10.1111/jdv.15653
Crowley, J., Thaçi, D., Joly, P., Peris, K., Papp, K. A., Goncalves, J., Day, R. M., Chen, R., Shah, K., Ferrándiz, C., & Cather, J. C. (2017). Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). Journal of the American Academy of Dermatology, 77(2), 310–317.e1. https://doi.org/10.1016/j.jaad.2017.01.052
Dattola, A., Cannizzaro, M. V., Mazzeo, M., & Bianchi, L. (2017). Certolizumab pegol in the treatment of psoriasis and psoriatic arthritis: Preliminary real-life data. Dermatology and Therapy, 7(4), 485–492. https://doi.org/10.1007/s13555-017-0208-z
de Ruiter, C. C., & Rustemeyer, T. (2022). Biologics can significantly improve dermatology life quality index (DLQI) in psoriatic patients: A systematic review. Psoriasis, 12, 99–112. https://doi.org/10.2147/ptt.s356568
Dommasch, E. D., Abuabara, K., Shin, D. B., Nguyen, J., Troxel, A. B., & Gelfand, J. M. (2011). The risk of infection and malignancy with tumor necrosis factor antagonists in adult patients with psoriatic disease: A systematic review and meta-analysis of randomized controlled trials. Journal of the American Academy of Dermatology, 64(6), 1035. https://doi.org/10.1016/j.jaad.2010.09.734
Egeberg, A., Andersen, Y. M. F., Halling-Overgaard, A. S., Alignahi, F., Thyssen, J. P., Burge, R., & Mallbris, L. (2020). Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis. Journal of the European Academy of Dermatology and Venereology, 34(1), 39–46. https://doi.org/10.1111/jdv.15920
Farahnik, B., Beroukhim, K., Abrouk, M., Nakamura, M., Zhu, T. H., Singh, R., Lee, K., Bhutani, T., & Koo, J. (2016). Brodalumab for the treatment of psoriasis: A review of phase III trials. Dermatology and Therapy, 6(2), 111. https://doi.org/10.1007/s13555-016-0121-x
Farahnik, B., Beroukhim, K., Zhu, T. H., Abrouk, M., Nakamura, M., Singh, R., Lee, K., Bhutani, T., & Koo, J. (2016). Ixekizumab for the treatment of psoriasis: A review of phase III trials. Dermatology and Therapy, 6(1), 25–37. https://doi.org/10.1007/s13555-016-0102-0
Feldman, S. R., Gordon, K. B., Bala, M., Evans, R., Li, S., Dooley, L. T., Guzzo, C., Patel, K., Menter, A., & Gottlieb, A. B. (2005). Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: A double-blind placebo-controlled trial. The British Journal of Dermatology, 152(5), 954–960. https://doi.org/10.1111/j.1365-2133.2005.06510.x
Galluzzo, M., Trovato, E., Talamonti, M., Caldarola, G., Di Nardo, L., Lazzeri, L., Mugheddu, C., Burlando, M., Balestri, R., Bernardini, N., Biondi, G., Vellucci, L., Russo, F., De Simone, C., Paganini, C., Rech, G., Cozzani, E. C., Atzori, L., Montesu, M. A., … Rubegni, P. (2024). Long-term persistence rate of secukinumab in psoriatic patients: A six-year multicenter, real-world experience, retrospective study. Journal of Clinical Medicine, 13(13). https://doi.org/10.3390/jcm13133864
Gao, B., Shentu, H., Sha, S., Wang, D., Chen, X., Huang, Z., Dong, N., Lai, H., Xu, J., & Zhou, X. (2023). Efficacy of IL-23 inhibitors and IL-12/23 inhibitors in the induction treatment of Crohn’s disease: A meta-analysis based on randomized controlled trials. Central-European Journal of Immunology, 48(4), 301–310. https://doi.org/10.5114/ceji.2023.134257
Gao, L., Gu, L., Chen, Z., & Cao, S. (2020). Tildrakizumab: An evidence-based review of its use in the treatment of moderate-to-severe chronic plaque psoriasis. Therapeutics and Clinical Risk Management, 16, 903–916. https://doi.org/10.2147/TCRM.S227880
Gao, S., Xie, X., Fan, L., & Yu, L. (2025). Efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors for psoriatic arthritis: A network meta-analysis of randomized controlled trials. Frontiers in Immunology, 16. https://doi.org/10.3389/fimmu.2025.1654343
Gao, Y., Xu, T., Wang, Y., Hu, Y., Yin, S., Qin, Z., & Yu, H. (2025). Pathophysiology and treatment of psoriasis: From clinical practice to basic research. Pharmaceutics, 17(1), 56. https://doi.org/10.3390/pharmaceutics17010056
Girolomoni, G., Strohal, R., Puig, L., Bachelez, H., Barker, J., Boehncke, W. H., & Prinz, J. C. (2017a). The role of IL-23 and the IL-23/TH17 immune axis in the pathogenesis and treatment of psoriasis. Journal of the European Academy of Dermatology and Venereology, 31(10), 1616–1626. https://doi.org/10.1111/jdv.14433
Girolomoni, G., Strohal, R., Puig, L., Bachelez, H., Barker, J., Boehncke, W. H., & Prinz, J. C. (2017b). The role of IL-23 and the IL-23/TH17 immune axis in the pathogenesis and treatment of psoriasis. Journal of the European Academy of Dermatology and Venereology, 31(10), 1616. https://doi.org/10.1111/jdv.14433
Glatt, S., Baeten, D., Baker, T., Griffiths, M., Ionescu, L., Lawson, A. D. G., Maroof, A., Oliver, R., Popa, S., Strimenopoulou, F., Vajjah, P., Watling, M. I. L., Yeremenko, N., Miossec, P., & Shaw, S. (2018). Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: Evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Annals of the Rheumatic Diseases, 77(4), 523–532. https://doi.org/10.1136/annrheumdis-2017-212127
Gniadecki, R., Bang, B., Bryld, L. E., Iversen, L., Lasthein, S., & Skov, L. (2015). Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. The British Journal of Dermatology, 172(1), 244–252. https://doi.org/10.1111/bjd.13343
Gooderham, M., & Papp, K. (2015). Selective phosphodiesterase inhibitors for psoriasis: Focus on apremilast. BioDrugs, 29(5), 327–339. https://doi.org/10.1007/s40259-015-0144-3
Gordon, K. B., Blauvelt, A., Papp, K. A., Langley, R. G., Luger, T., Ohtsuki, M., Reich, K., Amato, D., Ball, S. G., Braun, D. K., Cameron, G. S., Erickson, J., Konrad, R. J., Muram, T. M., Nickoloff, B. J., Osuntokun, O. O., Secrest, R. J., Zhao, F., Mallbris, L., & Leonardi, C. L. (2016). Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. New England Journal of Medicine, 375(4), 345–356. https://doi.org/10.1056/NEJMoa1512711
Gordon, K. B., Langley, R. G., Warren, R. B., Okubo, Y., Stein Gold, L., Merola, J. F., Peterson, L., Wixted, K., Cross, N., Deherder, D., & Thaçi, D. (2022). Bimekizumab safety in patients with moderate to severe plaque psoriasis: Pooled results from phase 2 and phase 3 randomized clinical trials. JAMA Dermatology, 158(7), 735–744. https://doi.org/10.1001/jamadermatol.2022.1185
Gordon, K. B., Strober, B., Lebwohl, M., Augustin, M., Blauvelt, A., Poulin, Y., Papp, K. A., Sofen, H., Puig, L., Foley, P., Ohtsuki, M., Flack, M., Geng, Z., Gu, Y., Valdes, J. M., Thompson, E. H. Z., & Bachelez, H. (2018). Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): Results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. The Lancet, 392(10148), 650–661. https://doi.org/10.1016/S0140-6736(18)31713-6
Gordon, K., Papp, K., Poulin, Y., Gu, Y., Rozzo, S., & Sasso, E. H. (2012). Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL. Journal of the American Academy of Dermatology, 66(2), 241–251. https://doi.org/10.1016/j.jaad.2010.12.005
Gottlieb, A. B., Blauvelt, A., Thaçi, D., Leonardi, C. L., Poulin, Y., Drew, J., Peterson, L., Arendt, C., Burge, D., & Reich, K. (2018). Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). Journal of the American Academy of Dermatology, 79(2), 302–314.e6. https://doi.org/10.1016/j.jaad.2018.04.012
Gottlieb, A. B., Deodhar, A., McInnes, I. B., Baraliakos, X., Reich, K., Schreiber, S., Bao, W., Marfo, K., Richards, H. B., Pricop, L., Shete, A., Trivedi, V., Keefe, D., Papavassilis, C. C., Jagiello, P., Papanastasiou, P., Mease, P. J., & Lebwohl, M. (2022). Long-term safety of secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: Update on integrated pooled clinical trial and post-marketing surveillance data. Acta Dermato-Venereologica, 102, 563. https://doi.org/10.2340/actadv.v102.563
Griffiths, C. E. M., Papp, K. A., Song, M., Miller, M., You, Y., Shen, Y. K., Han, C., & Blauvelt, A. (2022). Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: Results from VOYAGE 1. Journal of Dermatological Treatment, 33(2), 1–9. https://doi.org/10.1080/09546634.2020.1782817
Griffiths, C. E. M., Strober, B. E., van de Kerkhof, P., Ho, V., Fidelus-Gort, R., Yeilding, N., Guzzo, C., Xia, Y., Zhou, B., Li, S., Dooley, L. T., Goldstein, N. H., & Menter, A. (2010). Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. The New England Journal of Medicine, 362(2), 118–128. https://doi.org/10.1056/NEJMoa0810652
Hagino, T., Saeki, H., Fujimoto, E., & Kanda, N. (2025). Effectiveness of long-term bimekizumab treatment and predictive factors for responders in moderate-to-severe psoriasis: A 52-week real-world study. The Journal of Dermatology, 52(2), 317–328. https://doi.org/10.1111/1346-8138.17532
Huang, X., Shentu, H., He, Y., Lai, H., Xu, C., Chen, M., & Zhu, H. (2023). Efficacy and safety of IL-23 inhibitors in the treatment of psoriatic arthritis: A meta-analysis based on randomized controlled trials. Immunologic Research, 71(4), 505–515. https://doi.org/10.1007/s12026-023-09366-4
European Medicines Agency. (n.d.). Ilumetri. Retrieved March 14, 2026, from https://www.ema.europa.eu/en/medicines/human/EPAR/ilumetri#overview
Jain, A., & Singh, J. A. (2013). Harms of tumor necrosis factor inhibitors in rheumatic diseases: A focused systematic review of the literature. Immunotherapy, 5(3), 265–293. https://doi.org/10.2217/imt.13.10
Kaszuba, A., Papanastasiou, P., Krasowska, D., De Lucas Laguna, R., Ziv, M., Ravichandran, S., Bansal, A., Dahale, S. S., Martin, R., Paguet, B., Magnolo, N., & Kingo, K. (2025). Long-term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236-week phase 3 trial results. Journal of the European Academy of Dermatology and Venereology. Advance online publication. https://doi.org/10.1111/jdv.70155
Kimball, A. B., Papp, K. A., Wasfi, Y., Chan, D., Bissonnette, R., Sofen, H., Yeilding, N., Li, S., Szapary, P., & Gordon, K. B. (2013). Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. Journal of the European Academy of Dermatology and Venereology, 27(12), 1535–1545. https://doi.org/10.1111/jdv.12046
Kruczek, W., Frątczak, A., Litwińska-Inglot, I., Polak, K., Pawlus, Z., Rutecka, P., Bergler-Czop, B., & Miziołek, B. (2025). Comparative analysis of the long-term real-world efficacy of interleukin-17 inhibitors in a cohort of patients with moderate-to-severe psoriasis treated in Poland. Journal of Clinical Medicine, 14(15). https://doi.org/10.3390/jcm14155421
Lambert, J., Hansen, J. B., Sohrt, A., & Puig, L. (2021). Dermatology life quality index in patients with moderate-to-severe plaque psoriasis treated with brodalumab or ustekinumab. Dermatology and Therapy, 11(4), 1265–1275. https://doi.org/10.1007/s13555-021-00545-5
Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., Rivas, E., Tsai, T.-F., Wasel, N., Tyring, S., Salko, T., Hampele, I., Notter, M., Karpov, A., Helou, S., & Papavassilis, C. (2014). Secukinumab in plaque psoriasis: Results of two phase 3 trials. The New England Journal of Medicine, 371(4), 326–338. https://doi.org/10.1056/NEJMoa1314258
Langley, R. G., Sofen, H., Dei-Cas, I., Reich, K., Sigurgeirsson, B., Warren, R. B., Paul, C., Szepietowski, J. C., Tsai, T. F., Hampele, I., You, R., Charef, P., & Papavassilis, C. (2023). Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: Results of a randomized extension of the phase III ERASURE and FIXTURE trials. The British Journal of Dermatology, 188(2), 198–207. https://doi.org/10.1093/bjd/ljac040
Lebwohl, M., Blauvelt, A., Paul, C., Sofen, H., Węgłowska, J., Piguet, V., Burge, D., Rolleri, R., Drew, J., Peterson, L., & Augustin, M. (2018). Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). Journal of the American Academy of Dermatology, 79(2), 266–276.e5. https://doi.org/10.1016/j.jaad.2018.04.013
Lebwohl, M. G., Carvalho, A., Asahina, A., Zhang, J., Fazeli, M. S., Kasireddy, E., Serafini, P., Ferro, T., Gogineni, R., & Thaçi, D. (2025). Biologics for the treatment of moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis. Dermatology and Therapy, 15(7), 1633–1656. https://doi.org/10.1007/s13555-025-01423-0
Lebwohl, M. G., Gordon, K. B., Gallo, G., Zhang, L., & Paul, C. (2020). Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: Results from UNCOVER-3 study. Journal of the European Academy of Dermatology and Venereology, 34(2), 301–309. https://doi.org/10.1111/jdv.15921
Lebwohl, M. G., Merola, J. F., Rowland, K., Miller, M., Yang, Y. W., Yu, J., You, Y., Chan, D., Thaçi, D., & Langley, R. G. (2023). Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: Pooled analyses across seven clinical trials with more than 8,600 patient-years of exposure. The British Journal of Dermatology, 189(1), 42–52. https://doi.org/10.1093/bjd/ljad115
Lebwohl, M., Papp, K., Han, C., Schenkel, B., Yeilding, N., Wang, Y., & Krueger, G. G. (2010). Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: Results from the PHOENIX 1 trial. The British Journal of Dermatology, 162(1), 137–146. https://doi.org/10.1111/j.1365-2133.2009.09491.x
Lebwohl, M., Song, E. J., Bhutani, T., Green, L., & Jacobson, A. (2025). Real-world evidence of brodalumab safety for the treatment of psoriasis. Journal of Psoriasis and Psoriatic Arthritis. Advance online publication. https://doi.org/10.1177/24755303251382878
Lebwohl, M., Strober, B., Menter, A., Gordon, K., Weglowska, J., Puig, L., Papp, K., Spelman, L., Toth, D., Kerdel, F., Armstrong, A. W., Stingl, G., Kimball, A. B., Bachelez, H., Wu, J. J., Crowley, J., Langley, R. G., Blicharski, T., Paul, C., … Nirula, A. (2015). Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. The New England Journal of Medicine, 373(14), 1318–1328. https://doi.org/10.1056/NEJMoa1503824
Leonardi, C. L., Kimball, A. B., Papp, K. A., Yeilding, N., Guzzo, C., Wang, Y., Li, S., Dooley, L. T., & Gordon, K. B. (2008). Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). The Lancet, 371(9625), 1665–1674. https://doi.org/10.1016/S0140-6736(08)60725-4
Leonardi, C. L., Powers, J. L., Matheson, R. T., Goffe, B. S., Zitnik, R., Wang, A., & Gottlieb, A. B. (2003). Etanercept as monotherapy in patients with psoriasis. The New England Journal of Medicine, 349(21), 2014–2022. https://doi.org/10.1056/NEJMoa030409
Leonardi, C., Reich, K., Foley, P., Torii, H., Gerdes, S., Guenther, L., Gooderham, M., Ferris, L. K., Griffiths, C. E. M., ElMaraghy, H., Crane, H., Patel, H., Burge, R., Gallo, G., Shrom, D., Leung, A., Lin, C.-Y., & Papp, K. (2020). Efficacy and safety of ixekizumab through 5 years in moderate-to-severe psoriasis: Long-term results from the UNCOVER-1 and UNCOVER-2 phase 3 randomized controlled trials. Dermatology and Therapy, 10(3), 431–447. https://doi.org/10.1007/s13555-020-00367-x
Liu, T., Li, S., Ying, S., Tang, S., Ding, Y., Li, Y., Qiao, J., & Fang, H. (2020). The IL-23/IL-17 pathway in inflammatory skin diseases: From bench to bedside. Frontiers in Immunology, 11. https://doi.org/10.3389/fimmu.2020.594735
Liu, Y., Li, Y., & Du, H. (2023). Efficacy of apremilast for psoriasis: A meta-analysis of randomized controlled studies. Postępy Dermatologii i Alergologii, 40(1), 165–170. https://doi.org/10.5114/ada.2022.119081
Long-term efficacy of guselkumab for the treatment of moderate-to-severe psoriasis: Results from the phase 3 VOYAGE 1 trial through two years. (n.d.). PubMed. Retrieved March 14, 2026, from https://pubmed.ncbi.nlm.nih.gov/30124721/
Long-term safety and efficacy of etanercept in patients with psoriasis: An open-label study. (n.d.). PubMed. Retrieved March 13, 2026, from https://pubmed.ncbi.nlm.nih.gov/20684143/
Lowes, M. A., Russell, C. B., Martin, D. A., Towne, J. E., & Krueger, J. G. (2013). The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends in Immunology, 34(4), 174–181. https://doi.org/10.1016/j.it.2012.11.005
Lowes, M. A., Suárez-Fariñas, M., & Krueger, J. G. (2014). Immunology of psoriasis. Annual Review of Immunology, 32, 227–255. https://doi.org/10.1146/annurev-immunol-032713-120225
Mariette, X., Förger, F., Abraham, B., Flynn, A. D., Moltó, A., Flipo, R. M., Van Tubergen, A., Shaughnessy, L., Simpson, J., Teil, M., Helmer, E., Wang, M., & Chakravarty, E. F. (2018). Lack of placental transfer of certolizumab pegol during pregnancy: Results from CRIB, a prospective, postmarketing, pharmacokinetic study. Annals of the Rheumatic Diseases, 77(2), 228–233. https://doi.org/10.1136/annrheumdis-2017-212196
Martin, D. A., Towne, J. E., Kricorian, G., Klekotka, P., Gudjonsson, J. E., Krueger, J. G., & Russell, C. B. (2013). The emerging role of IL-17 in the pathogenesis of psoriasis: Preclinical and clinical findings. Journal of Investigative Dermatology, 133(1), 17–26. https://doi.org/10.1038/jid.2012.194
Mastorino, L., Burzi, L., Frigatti, G., Fazio, A., Celoria, V., Macagno, N., Rosset, F., Passerini, S. G., Roccuzzo, G., Verrone, A., Stroppiana, E., Ortoncelli, M., Dapavo, P., Quaglino, P., & Ribero, S. (2023). Clinical effectiveness of IL-17 and IL-23 inhibitors on difficult-to-treat psoriasis areas (scalp, genital, and palmoplantar sites): A retrospective, observational, single-center, real-life study. Expert Opinion on Biological Therapy, 23(9), 929–936. https://doi.org/10.1080/14712598.2023.2236023
Mease, P. J., Hatemi, G., Paris, M., Cheng, S., Maes, P., Zhang, W., Shi, R., Flower, A., Picard, H., & Stein Gold, L. (2023). Apremilast long-term safety up to 5 years from 15 pooled randomized, placebo-controlled studies of psoriasis, psoriatic arthritis, and Behçet’s syndrome. American Journal of Clinical Dermatology, 24(5), 809–820. https://doi.org/10.1007/s40257-023-00783-7
Mease, P. J., Kivitz, A. J., Burch, F. X., Siegel, E. L., Cohen, S. B., Ory, P., Salonen, D., Rubenstein, J., Sharp, J. T., & Tsuji, W. (2004). Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression. Arthritis & Rheumatism, 50(7), 2264–2272. https://doi.org/10.1002/art.20335
Mease, P. J., Ory, P., Sharp, J. T., Ritchlin, C. T., Van Den Bosch, F., Wellborne, F., Birbara, C., Thomson, G. T. D., Perdok, R. J., Medich, J., Wong, R. L., & Gladman, D. D. (2009). Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Annals of the Rheumatic Diseases, 68(5), 702–709. https://doi.org/10.1136/ard.2008.092767
Megna, M., D’Agostino, M., Feo, F., Ventura, V., Tommasino, N., & Potestio, L. (2026). IL-23 inhibitors in psoriasis: What have we learnt so far? Journal of Inflammation Research, 19. https://doi.org/10.2147/JIR.S540848
Menter, A., Krueger, G. G., Paek, S. Y., Kivelevitch, D., Adamopoulos, I. E., & Langley, R. G. (2021). Interleukin-17 and interleukin-23: A narrative review of mechanisms of action in psoriasis and associated comorbidities. Dermatology and Therapy, 11(2), 385–403. https://doi.org/10.1007/s13555-021-00483-2
Menter, A., Papp, K. A., Gooderham, M., Pariser, D. M., Augustin, M., Kerdel, F. A., Fakharzadeh, S., Goyal, K., Calabro, S., Langholff, W., Chavers, S., Naessens, D., Sermon, J., & Krueger, G. G. (2016). Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: Results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Journal of the European Academy of Dermatology and Venereology, 30(7), 1148–1158. https://doi.org/10.1111/jdv.13611
Motedayen Aval, L., Yiu, Z. Z. N., Alabas, O. A., Griffiths, C. E. M., Reynolds, N. J., Hampton, P. J., Smith, C. H., & Warren, R. B. (2025). Drug survival of IL-23 and IL-17 inhibitors versus other biologics for psoriasis: A British Association of Dermatologists Biologics and Immunomodulators Register cohort study. Journal of the European Academy of Dermatology and Venereology, 39(10), 1785–1795. https://doi.org/10.1111/jdv.20739
Mourad, A. I., & Gniadecki, R. (2021). Biologic drug survival in psoriasis: A systematic review and comparative meta-analysis. Frontiers in Medicine, 7. https://doi.org/10.3389/fmed.2020.625755
Mrowietz, U., Kragballe, K., Reich, K., Griffiths, C. E. M., Gu, Y., Wang, Y., & Rozzo, S. J. (2013). An assessment of adalimumab efficacy in three phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals. The British Journal of Dermatology, 168(2), 374–380. https://doi.org/10.1111/j.1365-2133.2012.11214.x
Nast, A., Smith, C., Spuls, P. I., Avila Valle, G., Bata-Csörgö, Z., Boonen, H., De Jong, E., Garcia-Doval, I., Gisondi, P., Kaur-Knudsen, D., Mahil, S., Mälkönen, T., Maul, J. T., Mburu, S., Mrowietz, U., Reich, K., Remenyik, E., Rønholt, K. M., Sator, P. G., … Dressler, C. (2020). EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris—Part 1: Treatment and monitoring recommendations. Journal of the European Academy of Dermatology and Venereology, 34(11), 2461–2498. https://doi.org/10.1111/jdv.16915
Papadavid, E., Rompoti, N., Theodoropoulos, K., Kokkalis, G., & Rigopoulos, D. (2018). Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis. Journal of the European Academy of Dermatology and Venereology, 32(7), 1173–1179. https://doi.org/10.1111/jdv.14832
Papp, K. A., Griffiths, C. E. M., Gordon, K., Lebwohl, M., Szapary, P. O., Wasfi, Y., Chan, D., Hsu, M. C., Ho, V., Ghislain, P. D., Strober, B., & Reich, K. (2013). Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: Final results from 5 years of follow-up. The British Journal of Dermatology, 168(4), 844–854. https://doi.org/10.1111/bjd.12214
Papp, K. A., Lebwohl, M. G., Puig, L., Ohtsuki, M., Beissert, S., Gooderham, M., Amin, A. Z., Wu, T., Rubant, S., Bialik, B., Ashley, D., Soliman, A. M., Chen, M. M., & Blauvelt, A. (2025). Long-term safety and efficacy of risankizumab to treat moderate-to-severe plaque psoriasis: Final LIMMitless phase 3, open-label extension trial results. American Journal of Clinical Dermatology, 26(5), 829–841. https://doi.org/10.1007/s40257-025-00964-6
Papp, K., Reich, K., Leonardi, C. L., Kircik, L., Chimenti, S., Langley, R. G. B., Hu, C. C., Stevens, R. M., Day, R. M., Gordon, K. B., Korman, N. J., & Griffiths, C. E. M. (2015). Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (ESTEEM 1). Journal of the American Academy of Dermatology, 73(1), 37–49. https://doi.org/10.1016/j.jaad.2015.03.049
Ponikowska, M., Hill, L., Lee, C. S., Barisone, M., Ponikowski, P., Aldossary, H. M., Jędrzejczyk, M., Kubielas, G., & Uchmanowicz, I. (2025). Cardiovascular disease and psoriasis. Dermatology and Therapy, 16(1), 155. https://doi.org/10.1007/s13555-025-01566-0
Puig, L., Costanzo, A., de Jong, E. M. G. J., Torres, T., Warren, R. B., Wapenaar, R., Wegner, S., Gorecki, P., Gramiccia, T., Jazra, M., Buyze, J., & Conrad, C. (2024). Guselkumab-treated patients with plaque psoriasis who achieved complete skin clearance for ≥156 consecutive weeks: A post hoc analysis from the VOYAGE 1 clinical trial. American Journal of Clinical Dermatology, 25(2), 315–325. https://doi.org/10.1007/s40257-023-00816-1
Puig, L., Lebwohl, M., Bachelez, H., Sobell, J., & Jacobson, A. A. (2020). Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial. Journal of the American Academy of Dermatology, 82(2), 352–359. https://doi.org/10.1016/j.jaad.2019.05.095
Reich, K., Armstrong, A. W., Foley, P., Song, M., Wasfi, Y., Randazzo, B., Li, S., Shen, Y. K., & Gordon, K. B. (2017). Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind VOYAGE 2 trial. Journal of the American Academy of Dermatology, 76(3), 418–431. https://doi.org/10.1016/j.jaad.2016.11.042
Reich, K., Iversen, L., Puig, L., Lambert, J., Mrowietz, U., Kaplan Saday, K., & Warren, R. B. (2022). Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: A post hoc pooled analysis of AMAGINE-2 and AMAGINE-3. Journal of the European Academy of Dermatology and Venereology, 36(8), 1275–1283. https://doi.org/10.1111/jdv.18068
Reich, K., Nestle, F. O., Papp, K., Ortonne, J. P., Evans, R., Guzzo, C., Li, S., Dooley, L. T., & Griffiths, C. E. M. (2005). Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial. The Lancet, 366(9494), 1367–1374. https://doi.org/10.1016/S0140-6736(05)67566-6
Reich, K., Papp, K. A., Armstrong, A. W., Wasfi, Y., Li, S., Shen, Y. K., Randazzo, B., Song, M., & Kimball, A. B. (2019). Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: A pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies. The British Journal of Dermatology, 180(5), 1039–1049. https://doi.org/10.1111/bjd.17454
Reich, K., Papp, K. A., Blauvelt, A., Langley, R. G., Armstrong, A., Warren, R. B., Gordon, K. B., Merola, J. F., Okubo, Y., Madden, C., Wang, M., Cioffi, C., Vanvoorden, V., & Lebwohl, M. (2021). Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): Efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo-controlled phase 3 trial. The Lancet, 397(10273), 487–498. https://doi.org/10.1016/S0140-6736(21)00125-2
Reich, K., Papp, K. A., Blauvelt, A., Tyring, S. K., Sinclair, R., Thaçi, D., Nograles, K., Mehta, A., Cichanowitz, N., Li, Q., Liu, K., La Rosa, C., Green, S., & Kimball, A. B. (2017). Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): Results from two randomised controlled, phase 3 trials. The Lancet, 390(10091), 276–288. https://doi.org/10.1016/S0140-6736(17)31279-5
Reich, K., Segaert, S., Van De Kerkhof, P., Durian, C., Boussuge, M. P., Paolozzi, L., Wajdula, J., & Boggs, R. (2009). Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis. Dermatology, 219(3), 239–249. https://doi.org/10.1159/000237871
Reich, K., Warren, R. B., Iversen, L., Puig, L., Pau-Charles, I., Igarashi, A., Ohtsuki, M., Falqués, M., Harmut, M., Rozzo, S., Lebwohl, M. G., Cantrell, W., Blauvelt, A., & Thaçi, D. (2019). Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: Pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. The British Journal of Dermatology, 182(3), 605. https://doi.org/10.1111/bjd.18232
Reich, K., Warren, R. B., Iversen, L., Puig, L., Pau-Charles, I., Igarashi, A., Ohtsuki, M., Falqués, M., Harmut, M., Rozzo, S., Lebwohl, M. G., Cantrell, W., Blauvelt, A., & Thaçi, D. (2020). Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: Pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. The British Journal of Dermatology, 182(3), 605–617. https://doi.org/10.1111/bjd.18232
Reich, K., Warren, R. B., Lebwohl, M., Gooderham, M., Strober, B., Langley, R. G., Paul, C., De Cuyper, D., Vanvoorden, V., Madden, C., Cioffi, C., Peterson, L., & Blauvelt, A. (2021). Bimekizumab versus secukinumab in plaque psoriasis. The New England Journal of Medicine, 385(2), 142–152. https://doi.org/10.1056/NEJMoa2102383
Revicki, D., Willian, M. K., Saurat, J. H., Papp, K. A., Ortonne, J. P., Sexton, C., & Camez, A. (2008). Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: Results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. The British Journal of Dermatology, 158(3), 549–557. https://doi.org/10.1111/j.1365-2133.2007.08236.x
Rich, P., Gooderham, M., Bachelez, H., Goncalves, J., Day, R. M., Chen, R., & Crowley, J. (2016). Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). Journal of the American Academy of Dermatology, 74(1), 134–142. https://doi.org/10.1016/j.jaad.2015.09.001
Rønholt, K., & Iversen, L. (2017). Old and new biological therapies for psoriasis. International Journal of Molecular Sciences, 18(11), 2297. https://doi.org/10.3390/ijms18112297
Sánchez-Rodríguez, G., & Puig, L. (2023). Pathogenic role of IL-17 and therapeutic targeting of IL-17F in psoriatic arthritis and spondyloarthropathies. International Journal of Molecular Sciences, 24(12). https://doi.org/10.3390/ijms241210305
Saurat, J. H., Stingl, G., Dubertret, L., Papp, K., Langley, R. G., Ortonne, J. P., Unnebrink, K., Kaul, M., & Camez, A. (2008). Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). The British Journal of Dermatology, 158(3), 558–566. https://doi.org/10.1111/j.1365-2133.2007.08315.x
Sbidian, E., Chaimani, A., Afach, S., Doney, L., Dressler, C., Hua, C., Mazaud, C., Phan, C., Hughes, C., Riddle, D., Naldi, L., Garcia-Doval, I., & Le Cleach, L. (2020). Systemic pharmacological treatments for chronic plaque psoriasis: A network meta-analysis. Cochrane Database of Systematic Reviews, 2020(1), Article CD011535. https://doi.org/10.1002/14651858.CD011535.pub3
Sbidian, E., Chaimani, A., Guelimi, R., Garcia-Doval, I., Hua, C., Hughes, C., Naldi, L., Kinberger, M., Afach, S., & Le Cleach, L. (2023). Systemic pharmacological treatments for chronic plaque psoriasis: A network meta-analysis. Cochrane Database of Systematic Reviews, 2023(7), Article CD011535. https://doi.org/10.1002/14651858.CD011535.pub6
Sbidian, E., Chaimani, A., Guelimi, R., Tai, C. C., Beytout, Q., Choudhary, C., Mubuanga Nkusu, A., Ollivier, C., Samaran, Q., Hughes, C., Afach, S., & Le Cleach, L. (2025). Systemic pharmacological treatments for chronic plaque psoriasis: A network meta-analysis. Cochrane Database of Systematic Reviews, 2025(8), Article CD011535. https://doi.org/10.1002/14651858.CD011535.pub7
Schreiber, S., Colombel, J. F., Feagan, B. G., Reich, K., Deodhar, A. A., McInnes, I. B., Porter, B., Das Gupta, A., Pricop, L., & Fox, T. (2019). Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: A retrospective analysis of pooled data from 21 clinical trials. Annals of the Rheumatic Diseases, 78(4), 473–479. https://doi.org/10.1136/annrheumdis-2018-214273
Sieminska, I., Pieniawska, M., & Grzywa, T. M. (2024). The immunology of psoriasis—Current concepts in pathogenesis. Clinical Reviews in Allergy & Immunology, 66(2), 164–184. https://doi.org/10.1007/s12016-024-08991-7
Simopoulou, T., Tsiogkas, S. G., Zafiriou, E., & Bogdanos, D. P. (2023). Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis. Drugs of Today, 59(3), 135–167. https://doi.org/10.1358/dot.2023.59.3.3419557
European Medicines Agency. (n.d.). Skyrizi. Retrieved March 14, 2026, from https://www.ema.europa.eu/en/medicines/human/EPAR/skyrizi
Smolen, J. S., Landewé, R., Bijlsma, J., Burmester, G., Chatzidionysiou, K., Dougados, M., Nam, J., Ramiro, S., Voshaar, M., Van Vollenhoven, R., Aletaha, D., Aringer, M., Boers, M., Buckley, C. D., Buttgereit, F., Bykerk, V., Cardiel, M., Combe, B., Cutolo, M., … Van Der Heijde, D. (2017). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals of the Rheumatic Diseases, 76(6), 960–977. https://doi.org/10.1136/annrheumdis-2016-210715
Sticherling, M., Nikkels, A. F., Hamza, A. M., Kwong, P., Szepietowski, J. C., El Sayed, M., Ghislain, P. D., Khotko, A. A., Patekar, M., Ortmann, C. E., Forrer, P., Papanastasiou, P., & Keefe, D. (2023). Secukinumab in pediatric patients with plaque psoriasis: Pooled safety analysis from two phase 3 randomized clinical trials. American Journal of Clinical Dermatology, 24(5), 821–835. https://doi.org/10.1007/s40257-023-00782-8
Strober, B., Tada, Y., Mrowietz, U., Lebwohl, M., Foley, P., Langley, R. G., Warren, R. B., Wang, M., Vanvoorden, V., Szilagyi, B., Ciaravino, V., & Paul, C. (2023). Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial. The British Journal of Dermatology, 188(6), 749–759. https://doi.org/10.1093/bjd/ljad035
European Medicines Agency. (n.d.). Taltz. Retrieved March 13, 2026, from https://www.ema.europa.eu/en/medicines/human/EPAR/taltz
Thomas, S. S., Borazan, N., Barroso, N., Duan, L., Taroumian, S., Kretzmann, B., Bardales, R., Elashoff, D., Vangala, S., & Furst, D. E. (2015). Comparative immunogenicity of TNF inhibitors: Impact on clinical efficacy and tolerability in the management of autoimmune diseases. A systematic review and meta-analysis. BioDrugs, 29(4), 241–258. https://doi.org/10.1007/s40259-015-0134-5
European Medicines Agency. (n.d.). Tremfya. Retrieved March 14, 2026, from https://www.ema.europa.eu/en/medicines/human/EPAR/tremfya
Tyring, S., Gottlieb, A., Papp, K., Gordon, K., Leonardi, C., Wang, A., Lalla, D., Woolley, M., Jahreis, A., Zitnik, R., Cella, D., & Krishnan, R. (2006). Etanercept and clinical outcomes, fatigue, and depression in psoriasis: Double-blind placebo-controlled randomised phase III trial. The Lancet, 367(9504), 29–35. https://doi.org/10.1016/S0140-6736(05)67763-X
Vidal, S., Puig, L., Carrascosa-Carrillo, J. M., González-Cantero, Á., Ruiz-Carrascosa, J. C., & Velasco-Pastor, A. M. (2021). From messengers to receptors in psoriasis: The role of IL-17RA in disease and treatment. International Journal of Molecular Sciences, 22(13). https://doi.org/10.3390/ijms22136740
Vuyyuru, S. K., Solitano, V., Hogan, M., MacDonald, J. K., Zayadi, A., Parker, C. E., Sands, B. E., Panaccione, R., Narula, N., Feagan, B. G., Singh, S., Jairath, V., & Ma, C. (2023). Efficacy and safety of IL-12/23 and IL-23 inhibitors for Crohn’s disease: Systematic review and meta-analysis. Digestive Diseases and Sciences, 68(9), 3702–3713. https://doi.org/10.1007/s10620-023-08014-z
Warren, R. B., Blauvelt, A., Bagel, J., Papp, K. A., Yamauchi, P., Armstrong, A., Langley, R. G., Vanvoorden, V., De Cuyper, D., Cioffi, C., Peterson, L., Cross, N., & Reich, K. (2021). Bimekizumab versus adalimumab in plaque psoriasis. The New England Journal of Medicine, 385(2), 130–141. https://doi.org/10.1056/NEJMoa2102388
Warren, R. B., Lebwohl, M., Thaçi, D., Gooderham, M., Pinter, A., Paul, C., Gisondi, P., Szilagyi, B., White, K., Deherder, D., Staelens, F., Lambert, J., & Strober, B. (2025). Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: Long-term results from the BE RADIANT phase IIIb trial open-label extension period. The British Journal of Dermatology, 193(1), 44–55. https://doi.org/10.1093/bjd/ljaf032
Warren, R. B., Smith, C. H., Yiu, Z. Z. N., Ashcroft, D. M., Barker, J. N. W. N., Burden, A. D., Lunt, M., McElhone, K., Ormerod, A. D., Owen, C. M., Reynolds, N. J., & Griffiths, C. E. M. (2015). Differential drug survival of biologic therapies for the treatment of psoriasis: A prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology, 135(11), 2632–2640. https://doi.org/10.1038/jid.2015.208
Wcisło-Dziadecka, D., Zbiciak-Nylec, M., Brzezińska-Wcisło, L., & Mazurek, U. (2016). TNF-α in a molecularly targeted therapy of psoriasis and psoriatic arthritis. Postgraduate Medical Journal, 92(1085), 172–178. https://doi.org/10.1136/postgradmedj-2015-133419
Yan, X., Shi, M., Wang, B., Zeng, L., Wang, H., Shi, J., Cui, Y., & Hou, S. (2025). Targeting nail psoriasis: IL-17A inhibitors demonstrate site-specific superiority over IL-23 inhibitor in a 24-week dermoscopy-guided real-world cohort. Frontiers in Immunology, 16. https://doi.org/10.3389/fimmu.2025.1573715
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Aleksandra Kujach, Julia Góralska
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
